Nadezhda Shilova

Dr. Nadezhda Shilova

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2023 in Parasites & Vectors
Verified
Journal Article
Open access
PDF file
Marinela ContrerasMarinela Contreras
Marinela Contreras
RRRita Vaz Rodrigues
Rita Vaz Rodrigues
LMLorena Mazuecos
Lorena Mazuecos
MVMargarita Villar
Margarita Villar
Sara JerónimoSara Jerónimo
Sara Jerónimo
Jose De La FuenteJose De La Fuente
Jose De La Fuente
Background: Alpha-Gal syndrome (AGS) is a tick-borne food allergy caused by IgE antibodies against the glycan galactose-alpha-1,3-galactose (α-Gal) present in glycoproteins and glycolipids from mammalian meat. To advance in the diagnosis and treatment of AGS, further research is needed to unravel the molecular and immune mechanisms underlying this syndrome. The objective of this study is the characterization of tick salivary components and proteins with and without α-Gal modifications involved in modulating human immune response against this carbohydrate. Methods: Protein and α-Gal content were determined in tick saliva components, and proteins were identified by proteomics analysis of tick saliva fractions. Pathophysiological changes were recorded in the zebrafish (Danio rerio) model after exposure to distinct Ixodes ricinus tick salivary components. Serum samples were collected from zebrafish at day 8 of exposure to determine anti-α-Gal, anti-glycan, and anti-tick saliva protein IgM antibody titers by enzyme-linked immunosorbent assay (ELISA). Results: Zebrafish treated with tick saliva and saliva protein fractions combined with non-protein fractions demonstrated significantly higher incidence of hemorrhagic type allergic reactions, abnormal behavioral patterns, or mortality when compared to the phosphate-buffered saline (PBS)-treated control group. The main tick salivary proteins identified in these fractions with possible functional implication in AGS were the secreted protein B7P208-salivary antigen p23 and metalloproteases. Anti-α-Gal and anti-tick salivary gland IgM antibody titers were significantly higher in distinct saliva protein fractions and deglycosylated saliva group when compared with PBS-treated controls. Anti-glycan antibodies showed group-related profiles. Conclusions: Results support the hypothesis that tick salivary biomolecules with and without α-Gal modifications are involved in modulating immune response against this carbohydrate. Graphical

19 September 2017 in Molecules
Verified
Journal Article
Open access
PDF file
ALAnna-Kristin Ludwig
Anna-Kristin Ludwig
MMMalwina Michalak
Malwina Michalak
NSNadezhda Shilova
Nadezhda Shilova
SASabine André
Sabine André
HKHerbert Kaltner
Herbert Kaltner
HGHans-Joachim Gabius
Hans-Joachim Gabius
Tissue lectins are emerging (patho)physiological effectors with broad significance. The capacity of adhesion/growth-regulatory galectins to form functional complexes with distinct cellular glycoconjugates is based on molecular selection of matching partners. Engineering of variants by changing the topological display of carbohydrate recognition domains (CRDs) provides tools to understand the inherent specificity of the functional pairing. We here illustrate its practical implementation in the case of human tandem-repeat-type galectin-8 (Gal-8). It is termed Gal-8 (NC) due to presence of two different CRDs at the N- and C-terminal positions. Gal-8N exhibits exceptionally high affinity for 3′-sialylated/sulfated β-galactosides. This protein is turned into a new homodimer, i.e., Gal-8 (NN), by engineering. The product maintained activity for lactose-inhibitable binding of glycans and glycoproteins. Preferential association with 3′-sialylated/sulfated (and 6-sulfated) β-galactosides was seen by glycan-array analysis when compared to the wild-type protein, which also strongly bound to ABH-type epitopes. Agglutination of erythrocytes documented functional bivalency. This result substantiates the potential for comparative functional studies between the variant and natural Gal-8 (NC)/Gal-8N.

27 March 2016 in Akusherstvo i ginekologiia
Verified
Journal Article
Closed access
MZMarina M Ziganshina
Marina M Ziganshina
NSNadezhda Shilova
Nadezhda Shilova
KKKhasbiullina N.R. Khasbiullina
Khasbiullina N.R. Khasbiullina
NMNovakovsky M.E. Novakovsky M
Novakovsky M.E. Novakovsky M
МNМарина Nikolaeva
Марина Nikolaeva
GSGennady T. Sukhikh
Gennady T. Sukhikh

25 August 2024 in Histochemistry and Cell Biology
Verified
Journal Article
Closed access
PDF file
NSNadezhda Shilova
Nadezhda Shilova
OGOxana E. Galanina
Oxana E. Galanina
SPSvetlana M. Polyakova
Svetlana M. Polyakova
ANAlexey Nokel
Alexey Nokel
GPGalina V. Pazynina
Galina V. Pazynina
Nicolai BovinNicolai Bovin
Nicolai Bovin

Verified
Journal Article
Open access
PDF file
KDKira Dobrochaeva
Kira Dobrochaeva
NKNailya Khasbiullina
Nailya Khasbiullina
NSNadezhda Shilova
Nadezhda Shilova
NANadezhda Antipova
Nadezhda Antipova
POPolina S. Obukhova
Polina S. Obukhova
Nicolai BovinNicolai Bovin
Nicolai Bovin
The level of human natural antibodies of immunoglobulin M isotype against LeC in patients with breast cancer is lower than in healthy women. The epitope specificity of these antibodies has been characterized using a printed glycan array and enzyme-linked immunosorbent assay (ELISA), the antibodies being isolated from donors’ blood using LeC-Sepharose (LeC is Galβ1-3GlcNAcβ). The isolated antibodies recognize the disaccharide but do not bind to glycans terminated with LeC, which implies the impossibility of binding to regular glycoproteins of non-malignant cells. The avidity (as dissociation constant value) of antibodies probed with a multivalent disaccharide is 10−9 M; the nanomolar level indicates that the concentration is sufficient for physiological binding to the cognate antigen. Testing of several breast cancer cell lines showed the strongest binding to ZR 75-1. Interestingly, only 7% of the cells were positive in a monolayer with a low density, increasing up to 96% at highest density. The enhanced interaction (instead of the expected inhibition) of antibodies with ZR 75-1 cells in the presence of Galβ1-3GlcNAcβ disaccharide, indicates that the target epitope of anti-LeC antibodies is a molecular pattern with a carbohydrate constituent rather than a glycan.

29 December 2023 in Marine Drugs
Verified
Journal Article
Open access
PDF file
TMTatyana Mizgina
Tatyana Mizgina
Irina ChikalovetsIrina Chikalovets
Irina Chikalovets
TBTatyana A. Bulanova
Tatyana A. Bulanova
VMValentina I. Molchanova
Valentina I. Molchanova
AFAlina Filshtein
Alina Filshtein
Oleg ChernikovOleg Chernikov
Oleg Chernikov
In this study, a new l-rhamnose-binding lectin (GYL-R) from the hemolymph of bivalve Glycymeris yessoensis was purified using affinity and ion-exchange chromatography and functionally characterized. Lectin antimicrobial activity was examined in different ways. The lectin was inhibited by saccharides possessing the same configuration of hydroxyl groups at C-2 and C-4, such as l-rhamnose, d-galactose, lactose, l-arabinose and raffinose. Using the glycan microarray approach, natural carbohydrate ligands were established for GYL-R as l-Rha and glycans containing the α-Gal residue in the terminal position. The GYL-R molecular mass determined by MALDI-TOF mass spectrometry was 30,415 Da. The hemagglutination activity of the lectin was not affected by metal ions. The lectin was stable up to 75 °C and between pH 4.0 and 12.0. The amino acid sequence of the five GYL-R segments was obtained with nano-ESI MS/MS and contained both YGR and DPC-peptide motifs which are conserved in most of the l-rhamnose-binding lectin carbohydrate recognition domains. Circular dichroism confirmed that GYL is a α/β-protein with a predominance of the random coil. Furthermore, GYL-R was able to bind and suppress the growth of the Gram-negative bacteria E. coli by recognizing lipopolysaccharides. Together, these results suggest that GYL-R is a new member of the RBL family which participates in the self-defense mechanism against bacteria and pathogens with a distinct carbohydrate-binding specificity.